- Benign Prostatic Hyperplasia
- Hormone Therapy
- Genomic Testing
- Next-Generation Imaging
- UTUC
- OAB and Incontinence
- Genitourinary Cancers
- Kidney Cancer
- Men's Health
- Pediatrics
- Female Urology
- Sexual Dysfunction
- Kidney Stones
- Urologic Surgery
- Bladder Cancer
- Benign Conditions
- Prostate Cancer
Key steps in pursuing a strategy of active surveillance for very low-risk prostate cancer
Christopher P. Evans, MD, discusses his active surveillance protocol with J. Brantley Thrasher, MD.
In this interview, Christopher P. Evans, MD, discusses the use of active surveillance in men with low-risk prostate cancer. Evans is professor and chair of the Department of Urologic Surgery at the University of California, Davis, School of Medicine. He was interviewed by Urology Times® Editorial Consultant J. Brantley Thrasher, MD, executive director of the American Board of Urology, Charlottesville, Virginia.
More videos:
App facilitates assessment of urologic chronic pelvic pain syndrome
Testosterone therapy does not appear to worsen outcomes in men with COVID-19
HIFU for prostate cancer: How it works, criteria for treatment, and contraindications
Cell-cycle risk score is predictive of ADT benefit in prostate cancer
May 17th 2024"Prolaris precisely describes the difference in metastasis outcomes for men receiving monotherapy (RT) vs multimodal therapy (RT+ADT), and further tells me precisely what the risk of death is for a man on surveillance," says Jonathan D. Tward, MD, PhD.
